Collectibles 2.0 Discussion: Dave Rodman & Tonya Evans

With the explosive introduction of non-fungible tokens ("NFTs") and their potential not only in the cryptocurrency industry but in mainstream media as well, there is an urgent need to understand the legal aspects and consequences of NFTs. Firm founder, David Rodman recently joined Penn State … Read more about Collectibles 2.0 Discussion: Dave Rodman & Tonya Evans

Firm Q&A: COVID’s Impact

COVID-19 has permeated virtually every aspect of our daily society, affecting millions of people and businesses across the country, and countless others overseas. In light of the impact of COVID19 and the confusion about the various aid and stimulus packages offered by the federal government, The … Read more about Firm Q&A: COVID’s Impact

Westword Publishes Managing Partner’s Article on CBD & Schedule I

Nearly a year after the passing of the Agriculture Improvement Act of 2018 (“2018 Farm Bill”), the industrial hemp and cannabidiol (“CBD”) markets are booming, yet ingestible products are still illegal according to the federal government. With mounting pressure on the U.S. Food and Drug … Read more about Westword Publishes Managing Partner’s Article on CBD & Schedule I

Crypto’s $42 Million in Q1 Lobbying

Despite doubt over the industry’s staying power and fluctuating market capitalization, cryptocurrency has made significant steps into the mainstream in recent years. Between 2017 and July 2018, researchers at the University of Cambridge found that millions of new user accounts entered the crypto … Read more about Crypto’s $42 Million in Q1 Lobbying

Founder and Managing Partner Selected to Testify at FDA Public Hearing

It is with great pride that we announce that our Founder and Managing Partner, Dave Rodman has been selected by the U.S. Food and Drug Administration (“FDA”) to give oral testimony  regarding the safety of products containing cannabis-derived compounds, specifically cannabidiol (“CBD”), at the … Read more about Founder and Managing Partner Selected to Testify at FDA Public Hearing